Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)

PHASE3CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Pleural Empyema
Interventions
DRUG

TPA (Tissue Plasminogen Activator)

Intrapleural administration of tPA 4 mg in 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days

DRUG

DNase

Intrapleural administration of DNase 5 mg diluted to 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days

OTHER

Placebo

Intrapleural administration of normal saline 10 ml (≤10 kg) or 20 ml (\>10 kg)

Trial Locations (6)

Unknown

Alberta Children's Hospital, Calgary

BC V6H 3N1

British Columbia Children's Hospital, Vancouver

L8N 3Z5

McMaster Children's Hospital, Hamilton

K1H 8L1

Children's Hospital of Eastern Ontario, Ottawa

M5G 1X8

The Hospital for Sick Children(SickKids), Toronto

H3T 1C5

CHU Sainte Justine, Montreal

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Children's Hospital of Eastern Ontario

OTHER

collaborator

St. Justine's Hospital

OTHER

collaborator

Unity Health Toronto

OTHER

collaborator

The Physicians' Services Incorporated Foundation

OTHER

collaborator

McMaster Children's Hospital

OTHER

collaborator

British Columbia Children's Hospital

OTHER

lead

The Hospital for Sick Children

OTHER

NCT01717742 - Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial) | Biotech Hunter | Biotech Hunter